Tevogen Bio (TVGN) holder files to sell 330,000 shares under Rule 144

Rhea-AI Filing Summary

Tevogen Bio Holdings Inc. insider plans to sell common stock under Rule 144. A holder has filed to sell 330,000 shares of Tevogen Bio common stock through Fidelity Brokerage Services LLC on or around 02/06/2026 on the NASDAQ, with an aggregate market value of $103,224.00.

The shares come from gifts received on 12/12/2025 (230,000 shares from Ryan Saad) and 12/16/2025 (100,000 shares from Kirt Desai). The filing also notes a prior sale of 15,500 Tevogen Bio shares for $5,116.55 on 12/31/2025 by Shrimad Rachandra Love & Care.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	330000	103224.00	198689921	02/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/12/2025	Gift	RYAN SAAD!			230000	12/12/2025	Not Applicable
Common	12/16/2025	Gift	KIRT! DESAI			100000	12/16/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shrimad Rachandra Love & Care 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059	TEVOGEN BIO HOLDINGS INC.	12/31/2025	15500	5116.55

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Tevogen Bio Holdings Inc. (TVGN) disclose?

The Form 144 discloses an intended sale of Tevogen Bio common shares under Rule 144. A holder plans to sell 330,000 shares through Fidelity Brokerage Services LLC on NASDAQ, providing notice of a potential resale of restricted or control securities.

How many Tevogen Bio (TVGN) shares are intended to be sold and on which exchange?

The notice covers an intended sale of 330,000 Tevogen Bio common shares. The filing lists Fidelity Brokerage Services LLC as broker and identifies NASDAQ as the securities exchange where the shares are expected to be sold around February 6, 2026.

How were the Tevogen Bio (TVGN) shares in this Form 144 acquired?

The shares were acquired as gifts in December 2025. The filing shows 230,000 common shares received on December 12, 2025 from Ryan Saad and 100,000 common shares received on December 16, 2025 from Kirt Desai, both noted with non-cash consideration descriptions.

What prior Tevogen Bio (TVGN) share sales are reported in the last three months?

The document reports that Shrimad Rachandra Love & Care sold 15,500 Tevogen Bio shares on December 31, 2025. The gross proceeds from that transaction were $5,116.55, and this sale is included to comply with Rule 144 aggregation requirements.

What market value and shares outstanding are noted in the Tevogen Bio (TVGN) Form 144?

For the planned 330,000-share sale, the filing lists an aggregate market value of $103,224.00. It also states that 198,689,921 shares of Tevogen Bio common stock were outstanding, providing context for the size of the potential sale relative to total shares.

Which broker is handling the planned Tevogen Bio (TVGN) Rule 144 sale?

The filing names Fidelity Brokerage Services LLC as the broker for the planned sale. The broker’s address is given as 245 Summer Street, Boston, MA 02110, and NASDAQ is identified as the exchange where the Tevogen Bio common shares are to be sold.